39 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University of Nebraska Medical Center
23829517	30	A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.	Palack£
32502343	79	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.	Harvard Medical School
32150405	75	CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?	Lebanese American University
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
30707835	18	Chemical Control of Mammalian Circadian Behavior through Dual Inhibition of Casein Kinase I? and ?.	Korea Institute of Science and Technology
31477350	80	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).	Eli Lilly
31514062	80	Recent advances in the development of cyclin-dependent kinase 7 inhibitors.	Tianjin University of Science and Technology
31098000	63	Discovery of CDK5 Inhibitors through Structure-Guided Approach.	University of South Australia
30943029	59	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.	Palack£
31693351	473	Discovery of 4	TBA
30733087	53	A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.	China Pharmaceutical University
30543440	86	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.	University of South Australia Cancer Research Institute
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
30234987	232	How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?	Palack£
31200237	95	Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.	Shanghai Pharmaceuticals Holding
29398441	111	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	Astrazeneca
30253346	46	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.	Chinese Academy of Sciences
29273417	26	An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.	University of Kwazulu-Natal
30067358	79	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.	Takeda Pharmaceutical
29853338	31	Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.	Shihezi University
28827110	54	Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.	Korea Research Institute of Chemical Technology
28956923	34	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.	Chinese Academy of Sciences